Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.
Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken AC, Hansmeier AA, Evers G, Mikesch JH, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters RM, Krug U, Kropff MH, Thoennissen NH, Berdel WE. Thoennissen GB, et al. Among authors: kropff mh. Acta Haematol. 2017;137(3):163-172. doi: 10.1159/000463534. Epub 2017 Apr 12. Acta Haematol. 2017. PMID: 28399522 Free article.
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M, Mitterer M, Südhoff T, Fenk R, Straka C, Heinecke A, Koch OM, Ostermann H, Berdel WE, Kienast J. Kropff MH, et al. Br J Haematol. 2003 Aug;122(4):607-16. doi: 10.1046/j.1365-2141.2003.04473.x. Br J Haematol. 2003. PMID: 12899716 Free article. Clinical Trial.
High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
Fenk R, Schneider P, Kropff M, Huenerlituerkoglu AN, Steidl U, Aul C, Hildebrandt B, Haas R, Heyll A, Kobbe G; West German Myeloma Study Group. Fenk R, et al. Br J Haematol. 2005 Aug;130(4):588-94. doi: 10.1111/j.1365-2141.2005.05641.x. Br J Haematol. 2005. PMID: 16098074 Free article. Clinical Trial.
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.
Bisping G, Kropff M, Wenning D, Dreyer B, Bessonov S, Hilberg F, Roth GJ, Munzert G, Stefanic M, Stelljes M, Scheffold C, Müller-Tidow C, Liebisch P, Lang N, Tchinda J, Serve HL, Mesters RM, Berdel WE, Kienast J. Bisping G, et al. Blood. 2006 Mar 1;107(5):2079-89. doi: 10.1182/blood-2004-11-4250. Epub 2005 Nov 8. Blood. 2006. PMID: 16278310 Free article.
Proteasome inhibition in multiple myeloma.
Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J. Kropff M, et al. Eur J Cancer. 2006 Jul;42(11):1623-39. doi: 10.1016/j.ejca.2006.02.015. Epub 2006 Jul 3. Eur J Cancer. 2006. PMID: 16820291 Review.
62 results